Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-Rad ABLTS:0R44 -3.17%83 5-Year Yield-on-Cost % is 0.26 as of Jul. 31, 2026, which is 4% below its 10-year median of 0.27. GuruFocus rates LTS:0R44 with a GF Score™ of 83/100 and a GF Value™ of kr33.41 (Fairly Valued). The stock has 4 warning signs investors should review. Among 319 Medical Devices & Instruments companies, C-Rad AB ranks worse than 94.67% on this metric.
C-Rad AB's yield on cost for the quarter that ended in Jun. 2026 was 0.26.
The historical rank and industry rank for C-Rad AB's 5-Year Yield-on-Cost % or its related term are showing as below:
LTS:0R44'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.26 Med: 0.27 Max: 0.28
Current: 0.26
During the past 13 years, C-Rad AB's highest Yield on Cost was 0.28. The lowest was 0.26. And the median was 0.27.
LTS:0R44's 5-Year Yield-on-Cost % is ranked worse than 94.67% of 319
companies
in the Medical Devices & Instruments industry
Industry Median: 2.45
vs LTS:0R44: 0.26
C-Rad AB (LTS:0R44) 5-Year Yield-on-Cost % Explanation
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
C-Rad AB 5-Year Yield-on-Cost % Related Terms
LTS:0R44 vs ABT, SYK, MDT: 5-Year Yield-on-Cost % Comparison
For the Medical Devices subindustry, C-Rad AB's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB 5-Year Yield-on-Cost % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where C-Rad AB's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of C-Rad AB is calculated as
C-Rad AB (LTS:0R44) has a 5-Year Yield-on-Cost % of 0.26 as of Jul. 31, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on C-Rad AB and its competitors. This is near median its historical median of 0.27. Over the past decade, C-Rad AB's 5-Year Yield-on-Cost % has ranged from 0.26 to 0.28. According to the industry distribution chart, C-Rad AB ranks #302 out of 319 companies in the Medical Devices & Instruments industry, placing it in the top 94.7%.
Is C-Rad AB's 5-Year Yield-on-Cost % too high?
C-Rad AB's current 5-Year Yield-on-Cost % of 0.26 is near median its 10-year median of 0.27. Over the past 10 years, this metric has ranged from a low of 0.26 to a high of 0.28. The Medical Devices & Instruments industry median 5-Year Yield-on-Cost % is 2.45. C-Rad AB's value of 0.26 is 89.4% below this industry median. Based on the distribution chart, C-Rad AB ranks #302 out of 319 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, C-Rad AB has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's 5-Year Yield-on-Cost % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, C-Rad AB ranks #302 out of 319 companies for 5-Year Yield-on-Cost %. This places C-Rad AB in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.45. C-Rad AB's value of 0.26 is 89.4% below this benchmark. Historically, C-Rad AB's own 5-Year Yield-on-Cost % has ranged from 0.26 to 0.28 over the past decade. While the company's 10-year median is 0.27 vs. the industry median of 2.45, C-Rad AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Devices & Instruments company?
The median 5-Year Yield-on-Cost % among Medical Devices & Instruments companies is 2.45, based on 319 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. C-Rad AB's current 5-Year Yield-on-Cost % of 0.26 is 89.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on C-Rad AB and its competitors. For the Medical Devices & Instruments industry, the median 5-Year Yield-on-Cost % is 2.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. C-Rad AB's current 5-Year Yield-on-Cost % is 0.26, which is near median its own 10-year median of 0.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
Based on GuruFocus' analysis, C-Rad AB (LTS:0R44) is currently considered Fairly Valued. The stock's GF Value™ is kr33.41, compared to a current price of kr36.70 — trading 9.8% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.26, which is near median its 10-year median of 0.27 and 89.4% below the Medical Devices & Instruments industry median of 2.45. C-Rad AB's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For C-Rad AB (LTS:0R44), the current 5-Year Yield-on-Cost % is 0.26 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (LTS:0R44) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of kr36.70 is trading 9.8% above its estimated GF Value™ of kr33.41.
GuruFocus considers C-Rad AB to be Fairly Valued.
Key valuation signals for LTS:0R44:
5-Year Yield-on-Cost %: 0.26 (near median its 10-year median of 0.27)
GF Value™: kr33.41 vs. price of kr36.70 (9.8% above fair value)
Industry Position: 89.4% below the Medical Devices & Instruments median (#302 of 319)
No single metric tells the full story. See the LTS:0R44 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
83GF Score
Get the complete analysis for LTS:0R44
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R44 has been successfully added to your 
